Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)

The National Institutes of Health (NIH) is inviting applications for the Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional) funding opportunity. This program aims to enhance understanding of the biobehavioral and neurobiological mechanisms underlying NPS in individuals with Alzheimer’s disease (AD) or Alzheimer’s disease-related dementias (ADRD). The findings are expected to identify novel therapeutic targets and advance interventions for preventing or treating NPS in AD/ADRD. Eligible applicants include state and local governments, higher education institutions, tribal entities, nonprofits, small businesses, and for-profit organizations. The program does not require cost-sharing or matching funds. Applications are due by January 6, 2025, with additional cycles open until September 7, 2026. Funding for each award is capped at $275,000. Projects may include mechanistic studies exploring the pathways leading to NPS, as well as preliminary research to inform the development of therapeutic strategies. Clinical trials are optional under this opportunity.